share_log

Even Though MannKind (NASDAQ:MNKD) Has Lost US$66m Market Cap in Last 7 Days, Shareholders Are Still up 392% Over 5 Years

Even Though MannKind (NASDAQ:MNKD) Has Lost US$66m Market Cap in Last 7 Days, Shareholders Are Still up 392% Over 5 Years

尽管曼恩凯德生物医疗(纳斯达克:MNKD)在过去7天内市值蒸发了6600万美元,但股东们仍然在过去5年中获利392%。
Simply Wall St ·  10/24 09:07

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held MannKind Corporation (NASDAQ:MNKD) shares for the last five years, while they gained 392%. This just goes to show the value creation that some businesses can achieve. Also pleasing for shareholders was the 12% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 7.0% in 90 days).

对许多人来说,在股市投资的主要目的是实现惊人的回报。多年来,我们看到了一些真正惊人的收益。想想那些持有纳斯达克(NASDAQ:MNKD)上市公司股票五年的明智投资者,他们的收益率为392%。这只是一个例子,显示了一些企业可以实现的价值创造。对股东们来说,过去三个月涨幅达到12%也让人满意。但这一举动很可能受到市场相对乐观的影响(在90天内上涨了7.0%)。

Although MannKind has shed US$66m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

尽管曼恩凯德生物医疗本周市值缩水了6600万美元,让我们来看看其更长期的基本趋势,看看是什么推动了回报。

While MannKind made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

虽然曼恩凯德生物医疗在过去一年中有微薄盈利,但我们认为市场当前可能更关注其营业收入增长。一般来说,我们认为这种公司更类似于亏损股票,因为实际利润非常低。股东们要想对一家公司增长利润持有信心,它必须增加营业收入。

In the last 5 years MannKind saw its revenue grow at 32% per year. Even measured against other revenue-focussed companies, that's a good result. Arguably, this is well and truly reflected in the strong share price gain of 38%(per year) over the same period. It's never too late to start following a top notch stock like MannKind, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

在过去的5年里,曼恩凯德生物医疗的营业收入每年增长32%。即使与其他以营业收入为重点的公司进行对比,也可以获得不错的结果。可以说,这已经清楚地反映在相同时期每年38%的强劲股价增长中。现在开始跟踪曼恩凯德等一流股票永远不算晚,因为一些长期赢家会持续几十年赢下去。从表面上看,这似乎是一个好机会,尽管我们注意到市场情绪已经非常积极。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。

big
NasdaqGM:MNKD Earnings and Revenue Growth October 24th 2024
纳斯达克纳斯达克GM:MNKD收益和营业收入增长2024年10月24日

It is of course excellent to see how MannKind has grown profits over the years, but the future is more important for shareholders. Take a more thorough look at MannKind's financial health with this free report on its balance sheet.

看到曼恩凯德生物医疗多年来的利润增长当然是好事,但未来对于股东来说更重要。通过免费报告查看曼恩凯德生物医疗资产负债表,更全面地了解其财务健康状况。

A Different Perspective

不同的观点

We're pleased to report that MannKind shareholders have received a total shareholder return of 60% over one year. That's better than the annualised return of 38% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 5 warning signs we've spotted with MannKind (including 2 which are potentially serious) .

我们很高兴地报告,曼恩凯德生物医疗股东在一年内获得了总股东回报率高达60%。这比过去五年平均回报率38%要好,这意味着公司最近的表现更出色。持乐观态度的人可能会将最近的TSR改善视为表明业务本身随着时间变得更好。我觉得长期观察股价作为业绩代理很有趣。但为了真正获得洞察力,我们还需要考虑其他信息。因此,您应该了解我们在曼恩凯德生物医疗发现的5个警示信号(其中包括两个可能较为严重的)。

Of course MannKind may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

当然,曼恩凯德生物医疗可能不是最好的股票选择。因此,您可能希望查看这些免费的成长股集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发